The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|12|2|85-96

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.2, 2012-02, pp. : 85-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs

By  

Current Drug Targets, Vol. 11, Iss. 3, 2010-03 ,pp. : 291-302

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

By  

Current Medicinal Chemistry, Vol. 22, Iss. 2, 2014-12 ,pp. : 237-263

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics

By  

Current Medicinal Chemistry, Vol. 7, Iss. 12, 2000-12 ,pp. : 1213-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

By  

Current Medicinal Chemistry, Vol. 16, Iss. 36, 2009-12 ,pp. : 4869-4888

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 9, 2002-09 ,pp. : 1037-1050

Bentham Science Publishers

Access to resources Recommend Favorite